Lung Cancer’s “Bodyguard System” Discovered by Singapore Scientists

Why It Matters

By exposing a cell‑surface mechanism that stabilizes resistant EGFR mutants, the research opens a viable route to extend the efficacy of existing targeted therapies and address a major cause of treatment failure in lung cancer.

Key Takeaways

• P2Y2‑integrin axis shields mutant EGFR from degradation
• ATP release activates P2Y2, forming protective barrier
• Knocking out P2Y2 eliminates mutant EGFR in resistant cells
• Kaempferol shrinks drug‑resistant EGFR tumors in mice
• Targeting surface P2Y2 offers new combinatorial therapy route

Pulse Analysis

The prevalence of EGFR mutations in Southeast Asian lung adenocarcinomas has driven a wave of targeted therapies, yet resistance inevitably emerges as tumors adapt. While first‑generation inhibitors suppress the oncogenic signal, mutant EGFR proteins persist far longer than normal receptors, hinting at an underlying protective network. Understanding why these proteins evade cellular recycling is crucial for extending patient survival and reducing relapse rates.

A genome‑wide CRISPR screen conducted by A*STAR scientists uncovered that cancer cells secrete excess ATP, which engages the purinergic receptor P2Y2 on the cell surface. Activated P2Y2 recruits integrin β1, forming a molecular “bodyguard” that physically isolates mutant EGFR from lysosomal degradation pathways. This extracellular shield maintains continuous signaling, fueling tumor growth despite drug pressure. The discovery reframes resistance as a spatial problem—protecting the mutant protein outside the cell rather than altering intracellular drug binding.

Therapeutically, the surface accessibility of P2Y2 makes it an attractive drug target. Genetic ablation of P2Y2 in resistant cell lines caused near‑complete loss of mutant EGFR, and treatment with kaempferol, a flavonoid found in cruciferous vegetables, significantly shrank xenograft tumors without affecting normal EGFR. These results suggest that combining P2Y2 antagonists with existing EGFR inhibitors could preempt or reverse resistance, offering a novel, potentially less toxic strategy for clinicians. Ongoing work will need to translate these preclinical insights into human trials, but the pathway promises a new lever to improve outcomes for patients battling EGFR‑mutant lung cancer.